Mizuho maintains Outperform on Senseonics, cuts target to $18

0 min read Updated on 16 Jul 2026, 02:42 AM

Reviewed by

Radhika SScanX News Team

AI Summary

Mizuho analyst Anthony Petrone maintained an Outperform rating on Senseonics Holdings but lowered the price target to $18 from $20. The rating indicates continued confidence in the company's performance potential despite the reduced valuation outlook.

*this image is generated using AI for illustrative purposes only.

Mizuho analyst Anthony Petrone maintained an Outperform rating for Senseonics Holdings while reducing the stock's price target to $18 from $20. The adjustment reflects a revised valuation outlook for the company listed on NASDAQ under the ticker SENS.

The rating affirmation indicates continued confidence in Senseonics Holdings' performance potential despite the lower price objective. The change in target price suggests a recalibration of expected returns rather than a shift in the fundamental investment thesis.

Metric	Value
Rating	Outperform
Previous Price Target	$20
New Price Target	$18
Ticker	SENS

Investors will monitor Senseonics Holdings' progress against the new $18 target set by Mizuho. The Outperform stance implies the stock is expected to deliver above-market returns relative to its sector peers.

What specific factors led Mizuho to revise the valuation outlook while maintaining the Outperform rating?

How might this price target adjustment influence other analysts' ratings for Senseonics Holdings?

What upcoming catalysts could help Senseonics reach the new $18 price target?

Read Next Article

Senseonics partners with Welldoc on Eversense 365 app development

0 min read Updated on 10 Jun 2026, 06:20 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

AI Summary

Senseonics and Welldoc have announced a strategic partnership to develop a custom mobile application for the Eversense 365 CGM system. The collaboration aims to integrate AI-powered health solutions to enhance diabetes management. The new app will focus on providing personalized insights and improving user experience.

*this image is generated using AI for illustrative purposes only.

Senseonics, a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, has partnered with Welldoc, a leader in AI-powered health solutions, to develop a new custom mobile application for Eversense 365. The strategic partnership aims to leverage Welldoc's expertise in AI to enhance the functionality and user experience of the Eversense 365 system. This collaboration marks a significant step in integrating advanced digital health solutions into diabetes management.

Partnership Details

The agreement focuses on the co-development of a tailored mobile application specifically designed for the Eversense 365 CGM system. By combining Senseonics' implantable sensor technology with Welldoc's AI-powered platform, the companies intend to provide a more comprehensive and intuitive tool for patients. The application will feature personalized insights and data-driven recommendations to support diabetes care.

Strategic Objectives

The primary objective of this partnership is to improve the overall user experience for individuals relying on the Eversense 365 system. The integration of AI capabilities is expected to offer real-time analytics and actionable health data. This move aligns with the growing trend of digital therapeutics in chronic disease management.

How will the integration of AI in the new app differentiate Eversense 365 from competing CGM systems?

What regulatory approvals will be required before the AI-powered app can be launched?

Could this partnership pave the way for similar collaborations in other chronic disease management areas?